BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35856444)

  • 21. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
    Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
    Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
    Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
    Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
    Dashti P; van de Peppel J; Thaler R; Paradise CR; Stein GS; Montecino MA; van Leeuwen JPTM; van der Eerden BJ; Dudakovic A; van Wijnen AJ
    Gene; 2023 Jan; 851():146928. PubMed ID: 36191822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2-dependent epigenetic modulation of histone H3 lysine-27 contributes to psoriasis by promoting keratinocyte proliferation.
    Zhang T; Yang L; Ke Y; Lei J; Shen S; Shao S; Zhang C; Zhu Z; Dang E; Wang G
    Cell Death Dis; 2020 Oct; 11(10):826. PubMed ID: 33011750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
    Chen XJ; An N
    J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
    Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
    Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone Morphogenetic Protein-2 Induces Non-Canonical Inflammatory and Oxidative Pathways in Human Retinal Endothelial Cells.
    Al-Shabrawey M; Hussein K; Wang F; Wan M; Elmasry K; Elsherbiny N; Saleh H; Yu PB; Tawfik A; Ibrahim AS
    Front Immunol; 2020; 11():568795. PubMed ID: 33584642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
    Fujii S; Ito K; Ito Y; Ochiai A
    J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2, a potential regulator of dental pulp inflammation and regeneration.
    Hui T; A P; Zhao Y; Wang C; Gao B; Zhang P; Wang J; Zhou X; Ye L
    J Endod; 2014 Aug; 40(8):1132-8. PubMed ID: 25069920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines.
    Barros R; Pereira B; Duluc I; Azevedo M; Mendes N; Camilo V; Jacobs RJ; Paulo P; Santos-Silva F; van Seuningen I; van den Brink GR; David L; Freund JN; Almeida R
    J Pathol; 2008 Aug; 215(4):411-20. PubMed ID: 18498120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model of Subarachnoid Hemorrhage.
    Luo Y; Fang Y; Kang R; Lenahan C; Gamdzyk M; Zhang Z; Okada T; Tang J; Chen S; Zhang JH
    Stroke; 2020 Nov; 51(11):3320-3331. PubMed ID: 32933418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.
    Ye J; Fu Y; Wang Z; Yu J
    Cell Biol Toxicol; 2022 Dec; 38(6):1047-1062. PubMed ID: 34545456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.
    Zeng X; Chen S; Huang H
    Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
    Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
    Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2-mediated development of therapeutic resistance in cancer.
    Kaur P; Shankar E; Gupta S
    Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
    Anwar T; Gonzalez ME; Kleer CG
    Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.